Global Interventional Oncology Market

Interventional Oncology Market Size, Share, Growth Analysis, By Product(Embolization Devices, Ablation Devices, and Support Devices), By Cancer Type(Liver Cancer, Kidney Cancer, Breast Cancer, Lung Cancer), By End-User(Hospitals, Ambulatory surgical centres, Specialty clinics, Others), By Procedure(Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy (TARE/SIRT), Transcatheter Arterial Chemoembolization (TACE), Thermal Tumor Ablation, and Transcatheter Arterial Embolization/Bland Embolization (TAE)), By End User(Hospitals, ambulatory surgery centers, and research & academic institutes), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35G2238 | Region: Global | Published Date: September, 2024
Pages: 242 | Tables: 147 | Figures: 78

Interventional Oncology Market Competitive Landscape

The competitive landscape of the global interventional oncology market is characterized by a mix of established players and emerging companies focusing on innovation and technological advancements. Key players include Medtronic, Boston Scientific, Siemens Healthineers, and Terumo Corporation, all of which are actively developing advanced devices and therapies. These companies emphasize collaborations and strategic partnerships to enhance their product portfolios and improve patient outcomes, driving competition and fostering continuous improvement in interventional oncology solutions worldwide.

Interventional Oncology Market Top Player's Company Profiles

  • Boston Scientific Corporation (US) 
  • Medtronic plc (Ireland) 
  • Johnson & Johnson (US) 
  • Terumo Corporation (Japan) 
  • Merit Medical Systems, Inc. (US) 
  • Teleflex, Inc. (US) 
  • AngioDynamics, Inc. (US) 
  • Becton, Dickinson and Company (US) 
  • Healthtronics, Inc. (US) 
  • Trod Medical (US) 
  • Sanarus Technologies, Inc. (US) 
  • Imbiotechnologies Ltd. (UK) 
  • Medwaves, Inc. (US) 
  • IceCure Medical (Israel) 
  • Cook Medical (US) 
  • Profound Medical Corp. (Canada) 
  • Sirtex Medical (Australia) 
  • Baylis Medical Company, Inc. (Canada) 
  • Accuray (US) 
  • Alpinion Medical Systems (South Korea)

Interventional Oncology Market Recent Development

  • In September 2023, Cook Medical announced the launch of its latest embolization device, designed for treating tumors more effectively with improved precision. This innovative device utilizes advanced imaging technology, enabling interventional radiologists to achieve better targeting and reduced complication rates, enhancing patient outcomes in interventional oncology procedures. 
  • In August 2023, Boston Scientific unveiled its next-generation radiofrequency ablation system for liver tumors. This system integrates advanced imaging techniques and real-time monitoring capabilities, allowing for more accurate treatment delivery. The launch reflects Boston Scientific's commitment to advancing minimally invasive oncology therapies and improving patient experiences during interventional procedures. 
  • In July 2023, Medtronic announced a significant collaboration with a leading oncology center to evaluate the effectiveness of its novel drug-coated balloons for treating liver cancers. This partnership aims to enhance clinical outcomes by leveraging Medtronic's innovative technologies, focusing on providing safer and more effective interventional oncology treatments for patients globally.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Interventional Oncology Market size was valued at USD 2.17 billion in 2022 and is poised to grow from USD 2.31 billion in 2023 to USD 3.92 billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031).

The competitive landscape of the global interventional oncology market is characterized by a mix of established players and emerging companies focusing on innovation and technological advancements. Key players include Medtronic, Boston Scientific, Siemens Healthineers, and Terumo Corporation, all of which are actively developing advanced devices and therapies. These companies emphasize collaborations and strategic partnerships to enhance their product portfolios and improve patient outcomes, driving competition and fostering continuous improvement in interventional oncology solutions worldwide. 'Boston Scientific Corporation (US) ', 'Medtronic plc (Ireland) ', 'Johnson & Johnson (US) ', 'Terumo Corporation (Japan) ', 'Merit Medical Systems, Inc. (US) ', 'Teleflex, Inc. (US) ', 'AngioDynamics, Inc. (US) ', 'Becton, Dickinson and Company (US) ', 'Healthtronics, Inc. (US) ', 'Trod Medical (US) ', 'Sanarus Technologies, Inc. (US) ', 'Imbiotechnologies Ltd. (UK) ', 'Medwaves, Inc. (US) ', 'IceCure Medical (Israel) ', 'Cook Medical (US) ', 'Profound Medical Corp. (Canada) ', 'Sirtex Medical (Australia) ', 'Baylis Medical Company, Inc. (Canada) ', 'Accuray (US) ', 'Alpinion Medical Systems (South Korea)'

The increasing prevalence of cancer globally is a significant driver of the interventional oncology market. With a growing aging population and lifestyle-related risk factors, the demand for effective cancer treatment options is escalating. This trend prompts healthcare providers to adopt innovative interventional procedures, enhancing patient outcomes and survival rates. 

Growing Adoption of Minimally Invasive Procedures: There is a significant trend toward minimally invasive interventional oncology techniques, driven by their ability to reduce recovery times and complications. Patients and healthcare providers increasingly favor these approaches, leading to the development and integration of advanced technologies that enhance precision and effectiveness in cancer treatment. 

North America dominates the global interventional oncology market due to a combination of advanced healthcare infrastructure, high levels of investment in research and development, and a strong presence of key market players. The region benefits from a growing number of cancer cases, which drives demand for innovative treatment options. Additionally, robust reimbursement policies and the adoption of minimally invasive techniques have contributed to increased procedure volumes. The presence of leading hospitals and specialized oncology centers facilitates cutting-edge treatments, further enhancing patient access. Furthermore, ongoing collaborations between healthcare providers and technology developers are accelerating advancements, solidifying North America's leadership in interventional oncology. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Interventional Oncology Market

Report ID: SQMIG35G2238

$5,300
BUY NOW GET FREE SAMPLE